Login / Signup

In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA.

Lukas VilligerTanja RothganglDominik WitzigmannRurika OkaPaulo J C LinWeihong QiSharan JanjuhaChristian BerkFemke RingnaldaMitchell B BeattieMarkus StoffelBeat ThönyJonathan HallHubert RehrauerRuben van BoxtelYing K TamGerald Schwank
Published in: Nature biomedical engineering (2021)
Base editors are RNA-programmable deaminases that enable precise single-base conversions in genomic DNA. However, off-target activity is a concern in the potential use of base editors to treat genetic diseases. Here, we report unbiased analyses of transcriptome-wide and genome-wide off-target modifications effected by cytidine base editors in the liver of mice with phenylketonuria. The intravenous delivery of intein-split cytidine base editors by dual adeno-associated viruses led to the repair of the disease-causing mutation without generating off-target mutations in the RNA and DNA of the hepatocytes. Moreover, the transient expression of a cytidine base editor mRNA and a relevant single-guide RNA intravenously delivered by lipid nanoparticles led to ~21% on-target editing and to the reversal of the disease phenotype; there were also no detectable transcriptome-wide and genome-wide off-target edits. Our findings support the feasibility of therapeutic cytidine base editing to treat genetic liver diseases.
Keyphrases
  • genome wide
  • crispr cas
  • dna methylation
  • copy number
  • nucleic acid
  • circulating tumor
  • single molecule
  • cell free
  • gene expression
  • type diabetes
  • low dose
  • high dose
  • poor prognosis
  • risk assessment
  • adipose tissue